Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P-gp Substrate.
Saved in:
| Title: | Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P-gp Substrate. |
|---|---|
| Authors: | Monk SA; Eli Lilly and Company, Indianapolis, Indiana., Kugler AR; AstraZeneca, Waltham, Massachusetts., Andersen SW; Eli Lilly and Company, Indianapolis, Indiana., Ayan-Oshodi MA; Eli Lilly and Company, Indianapolis, Indiana., James DE; Eli Lilly and Company, Indianapolis, Indiana., Mullen J; AstraZeneca, Waltham, Massachusetts., Zimmer JA; Eli Lilly and Company, Indianapolis, Indiana., Willis BA; Eli Lilly and Company, Indianapolis, Indiana. |
| Source: | Journal of clinical pharmacology [J Clin Pharmacol] 2020 May; Vol. 60 (5), pp. 586-594. Date of Electronic Publication: 2019 Dec 18. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
